DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

The Directorate General of Foreign Trade ( DGFT ) has notified an extension in the deadline for submitting applications for the export of Pharma Grade Sugar. This was communicated through Trade Notice No. 09/2025-26, dated July 22, 2025.

As per the latest trade notice, the revised deadline for submission of applications for obtaining Export Authorisation has been extended to July 31, 2025. This extension follows the earlier communication under Trade Notice No. 06/2025-26 issued on June 18, 2025, which had originally set the deadline.

The notice stated that “In continuation to the earlier Trade Notice No. 06/2025-26 dated June 18, 2025, the last date for submission of application for Export Authorisation for Pharma Grade Sugar, has been extended up to July 31, 2025. All other contents of the Trade Notice remains unchanged.”

Comprehensive Guide of Law and Procedure for Filing of Income Tax Appeals, Click Here

According to the directorate, all other terms and conditions mentioned in the earlier notice are still in effect. With the high standards and sensitive nature of exporting pharmaceutical-grade sugar, the delay is meant to provide exporters more time to finish the required paperwork and regulatory compliance.

This announcement has been circulated to all Regional Authorities of DGFT, Customs Commissionerates, and members of the trade community. For any further clarification, stakeholders have been advised to contact the DGFT.

Related Posts

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

CHENNAI: The Madras High Court on Friday dismissed a petition seeking to quash a First Information Report (FIR) registered against Puducherry-based pharmaceutical entities accused of manufacturing and distributing counterfeit medicines…

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

Chhattisgarh: Riding on policy reforms that earned it the top rank among large states in NITI Aayog’s Investment Friendliness Index 2026 for Regulatory Ease and Institutional Environment, Chhattisgarh has received…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

Pharma companies in a flux over Trump’s 200% tariff move on generics

Pharma companies in a flux over Trump’s 200% tariff move on generics

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’